- Immunosuppressanta's
- Anti-Inflammatory Drugs
- Corticosteroids
- Nonsteroidal anti-inflammatory drugs
- Biologics
Autoimmune Drugs Market was valued at USD 109,834 million in 2022 and is projected to reach USD 153,321 million by 2029, growing at a CAGR of 4.3% during 2023 to 2029. The immune system protects the body from the infections and diseases. In autoimmune disorders low or overactivity may appear. There is no exact causes of autoimmune diseases are identified. In response to unknown trigger, immune system produces antibodies that instead of fighting infections, attacks body own tissues. There are more than 80 autoimmune diseases are there and diagnosis varies from disease to disease based on the type of disease.Global Autoimmune Drugs market is driven by government initiatives towards increasing awareness in public about autoimmune disorders. In addition, increase in R&D investments and rising prevalence of autoimmune disorders are expected to boost the global autoimmune disease diagnostics market over the forecast period. Lack of standard treatment options, stringent regulatory framework may hinder the market for Autoimmune Drugs market globally.Market players are collaborating in order to develop the new molecules for the autoimmune diseases and further increasing their market portfolio. Furthermore, government and non-profit organizations are taking initiatives to increase the awareness and involving in development of drugs for autoimmune diseases.
Global Autoimmune Drugs Market Summary
Study Period
2023-29
Base Year
2022
CAGR
4.3%
Largest Market
North America
Fastest Growing Market
Asia-Pacific
Autoimmune Drugs Market Dynamics
Global Autoimmune Drugs market is expected to grow at significant rate owing to growing rates of autoimmune diseases. According to National Multiple Sclerosis Society (MS), approximately, 2.3 Mn people are living with multiple sclerosis worldwide. The market is composed of multinational and local companies involved in offering Autoimmune Drugs. Major players are involving in R&D for development and introduction of new drugs into the market.
North-America Got Significant Share
Autoimmune Drugs Market Regional Analysis
Geographically Autoimmune Drugs Market is segmented as Latin America, North America, Asia- Pacific, The Middle East & Africa and Europe. North America expected to be major market for Autoimmune Drugs owing to increase in prevalence of autoimmune disorders, presence of many market players, and government initiatives to promote the autoimmune disease awareness. Europe is expected to be another major market for global Autoimmune Drugs because of growing awareness and rising prevalence of autoimmune diseases. Asia Pacific expected to grow at faster rates owing to expansion of MNC's into the developing countries of the regions such as India and increase in R&D investment.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The autoimmune drugs market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup's details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Autoimmune Drugs Market Segmentation
By Drug Class
By Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa (MEA)
Frequently Asked Questions
The Autoimmune Drugs Market size was valued at USD 1,281.1 million in 2022
The Autoimmune Drugs Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
Asia Pacific is the fastest-growing for Autoimmune Drugs Market
| 1.Executive Summary |
| 2.Global Autoimmune Drugs Market Introduction |
| 2.1.Global Autoimmune Drugs Market - Taxonomy |
| 2.2.Global Autoimmune Drugs Market - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Distribution Channel |
| 2.2.3.Region |
| 3.Global Autoimmune Drugs Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Autoimmune Drugs Market Analysis, 2018-2022 and Forecast 2023-2029 |
| 4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Autoimmune Drugs Market By Drug Class, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 5.1. Immunosuppressanta's |
| 5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Anti-Inflammatory Drugs |
| 5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Corticosteroids |
| 5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Nonsteroidal anti-inflammatory drugs |
| 5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Biologics |
| 5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Autoimmune Drugs Market By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 6.1. Hospital Pharmacy |
| 6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Online Pharmacy |
| 6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Retail Pharmacy |
| 6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Autoimmune Drugs Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Autoimmune Drugs Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 8.1. Drug Class Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Immunosuppressanta's |
| 8.1.2.Anti-Inflammatory Drugs |
| 8.1.3.Corticosteroids |
| 8.1.4.Nonsteroidal anti-inflammatory drugs |
| 8.1.5.Biologics |
| 8.2. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Hospital Pharmacy |
| 8.2.2.Online Pharmacy |
| 8.2.3.Retail Pharmacy |
| 8.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Autoimmune Drugs Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 9.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Immunosuppressanta's |
| 9.1.2.Anti-Inflammatory Drugs |
| 9.1.3.Corticosteroids |
| 9.1.4.Nonsteroidal anti-inflammatory drugs |
| 9.1.5.Biologics |
| 9.2. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospital Pharmacy |
| 9.2.2.Online Pharmacy |
| 9.2.3.Retail Pharmacy |
| 9.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 9.3.6.Rest of EU |
| 10.Asia Pacific (APAC) Autoimmune Drugs Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Immunosuppressanta's |
| 10.1.2.Anti-Inflammatory Drugs |
| 10.1.3.Corticosteroids |
| 10.1.4.Nonsteroidal anti-inflammatory drugs |
| 10.1.5.Biologics |
| 10.2. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospital Pharmacy |
| 10.2.2.Online Pharmacy |
| 10.2.3.Retail Pharmacy |
| 10.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Autoimmune Drugs Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Immunosuppressanta's |
| 11.1.2.Anti-Inflammatory Drugs |
| 11.1.3.Corticosteroids |
| 11.1.4.Nonsteroidal anti-inflammatory drugs |
| 11.1.5.Biologics |
| 11.2. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospital Pharmacy |
| 11.2.2.Online Pharmacy |
| 11.2.3.Retail Pharmacy |
| 11.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Autoimmune Drugs Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Immunosuppressanta's |
| 12.1.2.Anti-Inflammatory Drugs |
| 12.1.3.Corticosteroids |
| 12.1.4.Nonsteroidal anti-inflammatory drugs |
| 12.1.5.Biologics |
| 12.2. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospital Pharmacy |
| 12.2.2.Online Pharmacy |
| 12.2.3.Retail Pharmacy |
| 12.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Allergan, Inc. (S.) |
| 13.2.2.AbbVie Inc., (U.S.) |
| 13.2.3.Takeda Pharmaceutical Company Limited (Japan) |
| 13.2.4.Bayer AG (Switzerland) |
| 13.2.5.Pfizer Inc. (US) |
| 13.2.6.Reddys (India) |
| 13.2.7.Novartis (Switzerland) |
| 13.2.8.Sanofi Avemtis (France) |
| 13.2.9.Eli Lilly (US) |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
- Allergan, Inc. (S.)
- AbbVie Inc., (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- Bayer AG (Switzerland)
- Pfizer Inc. (US)
- Reddys (India)
- Novartis (Switzerland)
- Sanofi Avemtis (France)
- Eli Lilly (US)